{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:41:45Z","timestamp":1792496505711,"version":"4.5.0"},"reference-count":36,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016982","name":"Yamagata University","doi-asserted-by":"publisher","award":["YU-COE (M)"],"award-info":[{"award-number":["YU-COE (M)"]}],"id":[{"id":"10.13039\/100016982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Metaplastic breast carcinoma (MpBC) is a rare and aggressive malignancy characterized by significant histological heterogeneity and limited response to standard chemotherapy. Due to its morphological diversity, MpBC often presents diagnostic challenges and can overlap with other mesenchymal tumors. This study aimed to characterize the genomic landscape of MpBC using a nationwide Japanese database and to explore the molecular basis of its diagnostic ambiguities and therapeutic responses. Methods: We retrospectively analyzed genomic and clinical data from 123 MpBC cases registered in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database. To evaluate diagnostic boundaries, genomic profiles of histological mimickers, including 19 cases of angiosarcoma and eight cases of myoepithelial carcinoma, were also examined. Furthermore, an exploratory single-cell RNA-sequencing analysis was performed on 3274 cells from independent MpBC datasets to investigate cellular heterogeneity and potential lineage plasticity. Results: TP53 (73.2%) and PIK3CA (46.0%) were the most prevalent genomic alterations in the MpBC cohort. Exploratory analysis suggested that PIK3CA mutations may be associated with an improved disease control rate in patients receiving taxane-based therapy (p = 0.028). Comparisons with mimickers identified distinctive molecular signatures, such as MED12 and HRAS hotspot mutations, across entities. Single-cell transcriptomics identified a distinct subpopulation (7.02% of malignant cells) co-expressing epithelial and phyllodes-like signatures. Conclusions: These findings suggest that MpBC harbors hybrid malignant cell populations that may contribute to its complex morphological diversity. While the therapeutic associations are based on a limited cohort and require prospective validation, the integration of comprehensive genomic and single-cell profiling provides an exploratory framework that may potentially enhance diagnostic accuracy in the future. However, these associations remain preliminary and require prospective validation to confirm their clinical utility.<\/jats:p>","DOI":"10.3390\/ph19020311","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:28:11Z","timestamp":1770910091000},"page":"311","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Genomic Landscape and Therapeutic Implications of Metaplastic Breast Carcinoma: Insights from a Nationwide Database Including Diagnostic Mimickers"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1975-0146","authenticated-orcid":false,"given":"Shuhei","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"},{"name":"Yamagata Hereditary Tumor Research Center, Yamagata University, 1-4-12 Kojirakawa, Yamagata 990-8560, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Seino","sequence":"additional","affiliation":[{"name":"Yamagata Hereditary Tumor Research Center, Yamagata University, 1-4-12 Kojirakawa, Yamagata 990-8560, Japan"},{"name":"Obstetrics and Gynecology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Sato","sequence":"additional","affiliation":[{"name":"Yamagata Hereditary Tumor Research Center, Yamagata University, 1-4-12 Kojirakawa, Yamagata 990-8560, Japan"},{"name":"Genomic Information, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Kawai","sequence":"additional","affiliation":[{"name":"Yamagata Hereditary Tumor Research Center, Yamagata University, 1-4-12 Kojirakawa, Yamagata 990-8560, Japan"},{"name":"Surgery I, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Ogura","sequence":"additional","affiliation":[{"name":"Pharmacology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hoshi","sequence":"additional","affiliation":[{"name":"Genetic Counseling, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0087-7905","authenticated-orcid":false,"given":"Koshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Kumanishi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahisa","family":"Fukui","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1245\/s10434-014-3890-4","article-title":"Survival outcomes of metaplastic breast cancer patients: Results from a US population-based analysis","volume":"22","author":"Nelson","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1245\/s10434-014-3782-7","article-title":"Hormone receptor status does not affect prognosis in metaplastic breast cancer: A population-based analysis with comparison to infiltrating ductal and lobular carcinomas","volume":"21","author":"Davis","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_3","unstructured":"WHO Classification of Tumours Editorial Board (2019). Breast Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41523-021-00302-z","article-title":"Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma","volume":"7","author":"Wong","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.5858\/arpa.2012-0166-CR","article-title":"Metaplastic carcinomas of the breast: Diagnostic challenges and new translational insights","volume":"136","author":"Rungta","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Suzuki, S., Seino, M., Sato, H., Kawai, M., Saito, Y., Saito, K., Yamada, Y., Takahashi, K., Kumanishi, R., and Fukui, T. (2025). Malignant Phyllodes Tumors: Diagnostic, Investigative and Therapeutic Challenges. Encyclopedia, 5.","DOI":"10.3390\/encyclopedia5040157"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Barrientos-Toro, E.N., Ding, Q., and Raso, M.G. (2024). Translational Aspects in Metaplastic Breast Carcinoma. Cancers, 16.","DOI":"10.3390\/cancers16071433"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/path.2004","article-title":"EGFR amplification and lack of activating mutations in metaplastic breast carcinomas","volume":"209","author":"Pinheiro","year":"2006","journal-title":"J. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","article-title":"C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan","volume":"12","author":"Kohno","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12282-024-01656-5","article-title":"A 5-year review of genomic medicine in breast cancer: Insights from C-CAT data on 3776 Japanese patients","volume":"32","author":"Morita","year":"2025","journal-title":"Breast Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Suzuki, S., Seino, M., Sato, H., Saito, Y., Saito, K., Yamada, Y., Takahashi, K., Kumanishi, R., and Fukui, T. (2025). Potential Resistance to Oxaliplatin-Based Regimens in Gastric Cancer Patients with ERBB2 R678Q Mutation: Evidence from a National Genomic Database. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47060430"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1634\/theoncologist.2017-0398","article-title":"Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010\u20132014","volume":"23","author":"Schroeder","year":"2018","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: The phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_15","first-page":"e62114","article-title":"Diagnostic Maze: Malignant Phyllodes Tumor Mimicking Metaplastic Breast Carcinoma","volume":"16","author":"Jayaraman","year":"2024","journal-title":"Cureus"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00428-021-03162-x","article-title":"Spindle cell lesions of the breast: A diagnostic approach","volume":"480","author":"Rakha","year":"2022","journal-title":"Virchows Arch."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/path.5091","article-title":"CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer","volume":"245","author":"Bartels","year":"2018","journal-title":"J. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Suzuki, S., and Saito, Y. (2024). Genomic Analysis of Advanced Phyllodes Tumors Using Next-Generation Sequencing and Their Chemotherapy Response: A Retrospective Study Using the C-CAT Database. Medicina, 60.","DOI":"10.20944\/preprints202411.0223.v1"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Gali\u00e8, M. (2019). RAS as Supporting Actor in Breast Cancer. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01199"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12032-023-02259-4","article-title":"Epithelial to mesenchymal transition (EMT) in metaplastic breast cancer and phyllodes breast tumors","volume":"41","author":"Akrida","year":"2023","journal-title":"Med. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1038\/s41467-017-02001-5","article-title":"Differentiation dynamics of mammary epithelial cells revealed by single-cell RNA sequencing","volume":"8","author":"Bach","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2559.1996.d01-510.x","article-title":"Mammary fibroadenoma and some phyllodes tumour stroma are composed of CD34+ fibroblasts and factor XIIIa+ dendrophages","volume":"29","author":"Silverman","year":"1996","journal-title":"Histopathology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-016-3853-5","article-title":"Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression","volume":"158","author":"Zhang","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/path.1067","article-title":"The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours","volume":"196","author":"Sawyer","year":"2002","journal-title":"J. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"84428","DOI":"10.18632\/oncotarget.12991","article-title":"MED12 mutations in breast phyllodes tumors: Evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways","volume":"7","author":"Gardrat","year":"2016","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.humpath.2020.11.009","article-title":"Expression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions","volume":"108","author":"Chen","year":"2021","journal-title":"Hum. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-010-1204-5","article-title":"Molecular classification of breast phyllodes tumors: Validation of the histologic grading scheme and insights into malignant progression","volume":"129","author":"Ang","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan After Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Dong, M., Shan, B., Han, X., Zhao, X., Wang, F., Zhu, L., Ou, Q., Ma, X., and Pan, Y. (2021). Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II\/III Breast Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.784985"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/bcr1984","article-title":"PIK3CA-activating mutations and chemotherapy sensitivity in stage II\u2013III breast cancer","volume":"10","author":"Liedtke","year":"2008","journal-title":"Breast Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2443.2007.01071.x","article-title":"The PI3K-Akt pathway promotes microtubule stabilization in migrating fibroblasts","volume":"12","author":"Onishi","year":"2007","journal-title":"Genes. Cells"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/bjc.2015.116","article-title":"Frequent MED12 mutations in phyllodes tumours of the breast","volume":"112","author":"Yoshida","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13058-024-01920-8","article-title":"A hybrid epithelial-mesenchymal transition program enables basal epithelial cells to bypass stress-induced stasis and contributes to a metaplastic breast cancer progenitor state","volume":"26","author":"Caruso","year":"2024","journal-title":"Breast Cancer Res."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/311\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:29:48Z","timestamp":1771046988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ph19020311"],"URL":"https:\/\/doi.org\/10.3390\/ph19020311","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}